Resverlogix Corp Sustainability Reports

Resverlogix Corp. is a late-stage clinical biotechnology company focused on developing epigenetic therapies to regulate disease-causing genes. Its primary clinical program evaluates its lead candidate, apabetalone, for treating cardiovascular disease and associated chronic conditions.

Sector: Manufacturing

Country: Canada

Exchange: Toronto Stock Exchange

LEI: 529900VI46SAPCOSH758

FIGI: BBG001SJQHY2

5 reports from 2021 to 2025

• Resverlogix Corp 2025 Consolidated Financial Statements
• Resverlogix Corp 2024 Consolidated Financial Statements
• Resverlogix Corp 2023 Consolidated Financial Statements
• Resverlogix Corp 2022 Consolidated Financial Statements
• Resverlogix Corp 2021 Consolidated Financial Statements